What's behind Monopar Therapeutics's latest 3.0% stock pullback?

Traders Union
All News
Stocks
Monopar therapeutics slides 3.04% today

Highlights

Shares of Monopar Therapeutics are trading at $108.86, down 3.04%, after an upside gap at the open.
Technical structure shows short-term selling pressure but maintains medium- and long-term bullish momentum with buyers still active intraday.
For the next five trading days, the price is forecast to range between $104.6075 and $113.1125, with 61% probability of an upward move.

Anton Kharitonov, expert at Traders Union, views Monopar Therapeutics' recent decline as a symptom of underlying uncertainty. He notes that mixed momentum readings and the absence of relevant news keep sentiment fragile. Kharitonov highlights that while buyers maintain some control, persistent technical selling pressure limits upside conviction. He sees the lack of news flow and sideways consolidation as signals to remain wary. "Unless Monopar decisively holds above $110.62, I see little justification for a bullish stance at these levels."

Viktoras Karapetjanc, expert at Traders Union, remains constructive on Monopar Therapeutics. He points to the stock's resilience above its 50-day and 200-day moving averages as confirmation of a strong bullish structure. Despite intraday selling, Karapetjanc believes the technical setup offers an attractive opportunity for further growth. He emphasizes that the market provides multiple setups for upside movement toward $113.1125 in the coming days. "I expect Monopar to capitalize on its robust foundation and push higher if resistance at $110.62 is cleared."

Parshwa Turakhiya, analyst, observes that Monopar's mixed technical signals and lack of news create a sentiment-driven short-term market. He sees immediate trading opportunity between support at $108.84 and resistance at $110.62. Turakhiya highlights the session's volatility as a cue for tactical traders to watch for momentum shifts. "For now, my focus is on swift reversals near intraday levels, with price action likely steering the next move."

Short-term seller pressure intensifies as mixed momentum tempers bullish structure

Monopar Therapeutics is trading below its 20-day moving average ($114.9085), while remaining above both the 50-day ($105.8002) and 200-day ($74.2399) moving averages. This pattern signals short-term seller pressure but confirms a bullish setup in the medium and long term. Immediate support is established at $108.84 (week low), and intraday resistance is noted at $110.62 (today low). Momentum indicators are sending mixed signals: MACD and ADX point to strong upward momentum, whereas RSI and CCI suggest mild oversold territory, and Stochastic RSI highlights selling pressure. Bull/Bear Power stays positive, indicating buyers still maintain control in intraday action, and the Awesome Oscillator supports an upward momentum bias. The current market position near the session low with intraday volatility at 1.57% reflects evident pressure after the open, as momentum indicators show a lack of clear directional conviction.

Earlier, analysts noted that Monopar Therapeutics was exhibiting longer-term technical strength despite ongoing short-term selling pressure. The current analysis introduces more balanced momentum signals and a slightly higher probability for upside, highlighting $108.84 as a key intraday support level to monitor for potential downside risk this week.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.